SC Ad6 1
Alternative Names: SC-Ad6-1Latest Information Update: 12 Jul 2021
At a glance
- Originator Tetherex Pharmaceuticals
- Class COVID-19 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I COVID 2019 infections
Most Recent Events
- 06 Jul 2021 Mayo Clinic in-licenses SC Ad6 1 from Tetherex Pharmaceuticals
- 28 Jun 2021 Phase-I clinical trials in COVID-2019 infections (Prevention, In adults) in Australia (IM) (NCT04839042)
- 28 Jun 2021 Phase-I clinical trials in COVID-2019 infections (Prevention, In adults) in Australia (Intranasal) (NCT04839042)